Quarterly ResultMay 12, 2026, 04:18 PM
Rezolute Ersodetug Phase 3 Shows Significant Glycemic Control
AI Summary
Rezolute reported its third quarter fiscal 2026 financial results and provided a business update, highlighting positive expanded analyses from the Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI). The study demonstrated significant and consistent improvements in glycemic control, including over 50% reduction in daily hypoglycemia time. The company's net loss improved to $16.2 million for the quarter, and it held $120.3 million in cash, cash equivalents, and investments.
Key Highlights
- Ersodetug Phase 3 sunRIZE study showed >50% reduction in daily hypoglycemia time by CGM.
- Weekly hypoglycemia events reduced by ~50-65% in ersodetug treatment arms.
- Average daily blood glucose increased by ~10-15 mg/dL in Phase 3 study.
- FDA encouraged submission of comprehensive analysis datasets for ersodetug in congenital HI.
- Cash, cash equivalents, and investments totaled $120.3 million as of March 31, 2026.
- Q3 Fiscal 2026 net loss improved to $16.2 million from $18.9 million year-over-year.
- Q3 Fiscal 2026 R&D expenses decreased to $11.4 million from $15.3 million YoY.